Valuation: Simulations Plus

Market Cap 374M 334M 311M 283M 534M 36.21B 536M 3.74B 1.47B 18.46B 1.41B 1.37B 59.24B P/E 2026 *
46.3x
P/E 2027 * 42x
Enterprise Value 374M 334M 311M 283M 534M 36.21B 536M 3.74B 1.47B 18.46B 1.41B 1.37B 59.24B EV / Sales 2026 *
4.57x
EV / Sales 2027 * 4.36x
Free-Float
99.98%
Yield 2026 *
-
Yield 2027 * -
1 week+0.05%
Current month+0.38%
1 month+0.43%
3 months+1.26%
6 months+42.31%
Current year+1.48%
1 week 18.49
Extreme 18.49
18.5
1 month 18.4
Extreme 18.4
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.1
Extreme 8.1011
90.92
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 1996-07-16
Director/Board Member 58 2014-12-02
Chairman 76 2024-12-16
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Issuer sale

Chairman

-23,547 0.1169%
10/6/26 Issuer sale

Chief Financial Officer

-109,600 0.5440%
10/6/26 Issuer sale

Founder

-3,207,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.05%+12.33%-57.65% 374M
+1.06%+0.87%+23.53%+33.13% 241B
+1.33%+3.07%+7.90%+1.03% 153B
+2.67%+8.85%-3.85%+44.88% 147B
+1.01%-0.60%-56.47%-19.19% 60.93B
+0.09%-1.10%+12.00%+15.52% 48.56B
+2.30%+3.38%-19.28%-16.69% 47.69B
+1.87%+2.25%+22.45%+54.17% 47.41B
+3.75%+7.68%-1.39%+38.07% 46.12B
+1.44%+2.54%+31.95%+63.31% 42.16B
Average +1.53%+0.34%+2.91%+15.66% 83.39B
Weighted average by Cap. +1.61%+0.46%+5.86%+24.57%

Financials

2026 *2027 *
Net sales 81.8M 73.05M 67.96M 61.81M 117M 7.92B 117M 818M 320M 4.04B 307M 300M 12.95B 85.76M 76.59M 71.25M 64.81M 122M 8.3B 123M 857M 336M 4.23B 322M 315M 13.58B
Net income 7.64M 6.82M 6.34M 5.77M 10.89M 739M 10.94M 76.34M 29.91M 377M 28.67M 28.04M 1.21B 9M 8.04M 7.47M 6.8M 12.84M 871M 12.89M 89.96M 35.25M 444M 33.79M 33.05M 1.42B
Net Debt - -
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
26-10-05 US$18.50 0.00% 625,309
26-10-02 US$18.50 +0.05% 460,260
26-10-01 US$18.49 +0.33% 865,859
26-09-30 US$18.43 -0.27% 332,435
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Simulations Plus